Business Wire

Xylem Expands Corporate Venture Capital Investments to $50M, Targeting Water Scarcity, Quality, and Decarbonization

Share

Global water technology leader Xylem (NYSE: XYL) is expanding its corporate venture investing plans with $50 million committed to support emerging companies and water services providers that solve critical climate challenges such as water scarcity, quality, and decarbonization.

Xylem aims to accelerate the availability of water solutions to address these challenges by directly investing in startups developing disruptive water technologies, and by investing in specialty venture capital funds. These investments are focused on companies developing cutting-edge solutions that support Xylem’s growth priorities, including advanced treatment, digital technology, and services to help manage complex water systems.

“As water scarcity intensifies and demand grows, the need for innovative thinking has never been more acute,” said Sivan Zamir, Vice President, Xylem Innovation Labs. “Entrepreneurial founders and disruptive new technologies can be important sources of solutions to tackle some of the world’s greatest water challenges. By collaborating with a broad network of partners, including venture capital firms and startups, we believe that we can bring essential innovations to market at speed and scale.”

Xylem’s expanded corporate venture capital framework builds on the success of existing partnerships. In 2022, Xylem invested a combined $20 million in Burnt Island Ventures, which targets early-stage water innovation, and The Westly Group, which focuses on energy, industry 4.0, and cybersecurity. (See 2022 announcement.) The framework also includes continuous evaluation of new investments in targeted venture capital funds, as well as minority investments in start-up companies.

About Xylem

Xylem (XYL) is a leading global water technology company committed to solving the world’s critical water challenges with innovation and expertise. Our 23,000 diverse employees delivered combined pro forma revenue of $8.1 billion in 2023. We are creating a more sustainable world by enabling our customers to optimize water and resource management and helping communities in more than 150 countries become water-secure. Join us at www.xylem.com and Let’s Solve Water.

Forward-looking statements

This press release contains “forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Generally, the words “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” "contemplate," "predict," “forecast,” “likely,” “believe,” “target,” “will,” “could,” “would,” “should,” "potential," "may" and similar expressions or their negative, may, but are not necessary to, identify forward-looking statements. By their nature, forward-looking statements address uncertain matters and include any statements that: are not historical, such as statements about our strategy, financial plans, outlook, objectives, plans, intentions or goals (including those related to our social, environmental and other sustainability goals); or address possible or future results of operations or financial performance, including statements relating to orders, revenues, operating margins and earnings per share growth.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and are subject to inherent risks and uncertainties, many of which are beyond our control. Important factors that could cause our actual results, performance and achievements, or industry results to differ materially from estimates or projections contained in or implied by our forward-looking statements include, among others, factors set forth under “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023 and in subsequent filings we make with the Securities and Exchange Commission. Readers of this press release are cautioned not to rely on any forward-looking statements since there can be no assurance that forward-looking statements will prove to be accurate. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240710808417/en/

Contacts

Houston Spencer
+1 (914) 323-5723
Houston.Spencer@xylem.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tyk Marks 10 Years in Business by Proving British Tech Can Grow Responsibly10.12.2025 10:30:00 EET | Press release

Tyk, the independent UK software company powering millions of digital transactions worldwide, is marking its tenth anniversary with B Corp certification - a milestone that recognises a decade of growth built on purpose, not hype. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209886821/en/ Tyk Founders, Martin Buhr (Left), James Hirst (Right) Founded in London in 2014 by Martin Buhr, Tyk began as a one-man side project and has grown into a company of 150 people in 30 countries. Its API management platform now underpins the digital infrastructure of banks, retailers and telcos across more than 100 markets including NatWest, SoundCloud, Zeiss, T-Mobile and Dollar General, powering over 100 million people’s financial transactions daily. From its inception, Tyk has challenged the conventions of the tech industry. It built a profitable business without offices or a “growth at all costs” mentality, long before remote-first work

Sainte Catherine, Institut du Cancer Avignon-Provence (ICAP), Becomes the First Center in Europe to Implement the Varian Latest Halcyon Advancements with Identify integration, PerfectKinetix Dynamic Couch and HyperSight for Personalized Radiotherapy10.12.2025 10:00:00 EET | Press release

Institut du Cancer Avignon-Provence (ICAP), and Varian, a Siemens Healthineers company, announced today the first European installation of the Halcyon version 5.0 radiotherapy platform, combined with IDENTIFY real-time motion management, and the PerfectKinetix Dynamic Couch. This milestone marks a significant step forward in delivering more precise, efficient, and personalized radiotherapy, while enhancing the overall patient experience. The latest evolution of Varian’s Halcyon platform brings together enhanced patient positioning, real-time motion management with IDENTIFY, and embedded high-quality HyperSight imaging. ICAP’s adoption of this ecosystem reflects its commitment to offering patients in the region access to the latest innovations in radiation oncology. Advancing Personalized Care The combination of Halcyon 5.0 and IDENTIFY 5.0 enables clinicians to deliver treatment more effectively by supporting individualized care plans. IDENTIFY* integration is designed to improve posit

L&T Technology Services, PALFINGER Inaugurate GDC as Part of Multi-Year Engagement to Accelerate Product Development10.12.2025 09:30:00 EET | Press release

L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced the inauguration of a state-of-the-art Global Development Center - APAC as part of a multi-year engagement with PALFINGER, an Austria-headquartered global pioneer in innovative crane and lifting solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209416315/en/ From PALFINGER, the ceremony was attended by Alexander Susanek (COO), Andreas Hille (Senior Vice President, Product Line Management and Engineering), Santhosh Rao (Senior Vice President Regional Sales & Service, Asia Pacific) and Arun C Bhongale (General Manager, SCM and Procurement). From LTTS, Mritunjay Singh (COO), Dr. Oliver Moron (Vice President, EU-DACH), Mohideen Farouk (Sales Director, EU-DACH), Jayant Joshi (Delivery Head, T&OH), Tejas B Shah (Delivery Head, Agriculture & Material Handling) and Sachin Nikam (Delivery Manager) we

New Study Reveals Surging Consumer Demand for Seamless Car-to-Home Audio10.12.2025 09:10:00 EET | Press release

Over 9 in 10 consumers say they are likely to seek out audio devices that allow smooth movement between car and home, according to a consumer survey conducted by Futuresource Consulting on behalf of Cinemo, a leading provider of in-car infotainment solutions and the company behind the first open cloud ecosystem connecting audio devices, content, and users. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209006640/en/ "From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience" Survey conducted by Futuresource Consulting on behalf of Cinemo; November 2025 The report, “From Living Room to Driver’s Seat: Exploring the Demands of a Unified Audio Experience”, drawn from more than 500 connected device users in China, where smart home and in-car connectivity adoption is among the highest globally, focused on four core themes: How consumers use audio across both home and in-car environments Their expect

Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 08:01:00 EET | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye